Position in CGON
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,421,000
+$1,104,161 QoQ
Shares Held
20,000
+162.1% QoQ
Ownership
0.023%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#109
of 226 holders
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Derivatives in CGON
reported options exposure · as of Jun 30, 2026CallValue
$8,803,095
CallShares
123,900
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026LMR Partners LLP holds $188,560,243 across 75 Biotechnology names. CGON ranks #27 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
134,214 | $40,402,439 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
223,995 | $21,835,032 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,306 | $13,908,683 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
347,106 | $10,850,533 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
5,112,098 | $8,521,240 | |
| 6 | ARGX |
Argenx SE
|
8,200 | $7,607,714 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
150,200 | $7,065,408 | |
| 8 | NKTR |
Nektar Therapeutics
|
100,000 | $6,981,000 |
All Filings in CGON
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,803,095 | 123,900 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $1,421,000 | 20,000 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $316,839 | 7,631 | Shares | Sole | 2026-02-17 | |
| 2024-06-30 | $429,857 | 13,616 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $597,742 | 13,616 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||